Novonesis, TurtleTree partner to scale lactoferrin
In Denmark, biosolutions giant Novonesis has entered into a development and commercialization pact with TurtleTree, an innovator in precision fermented ingredients such as lactoferrin LF+®. Simultaneously, Novonesis is making a minor investment in TurtleTree. 321Catalyst Ventures, the CVC-arm of Mitsui Chemicals, Inc. joins the investment.
Lactoferrin is a protein naturally found in milk and is recognized for its benefits across immunity, iron regulation, and gut health, particularly for women and infants. Traditional production requires large volumes of milk, leading to high costs, supply constraints, and environmental inefficiencies, preventing broad access to the health benefits that Lactoferrin provides.
Under the agreement, Novonesis will exclusively undertake efforts to scale, manufacture and commercialize LF+ for the early life nutrition market and will additionally have selected commercial rights for dietary supplements. The agreement with TurtleTree complements Novonesis’ pioneering efforts in precision fermentation and fits well into the existing Human Health Biosolutions portfolio of Human Milk Oligosaccharides, probiotics and synbiotics.
“Our aim is to make lactoferrin more accessible and cost-competitive and showcase what is achievable with precision fermentation in early life nutrition and dietary supplements,” Thomas Batchelor, Senior Vice President for Early Life and Specialized Nutrition at Novonesis, said in a press statement. “If successfully scaled, this will enable customers to deliver proven health benefits to consumers more efficiently. LF+®fits well in our broader portfolio of both precision fermentation projects and our specialized nutrition ingredients.”
Category: Chemicals & Materials
